EGFR and non-small cell lung carcinoma: The initial phase I/II study AURA and extensive phase II study AURA2 demonstrated impressive and exciting responses of osimertinib in EGFR-mutant advanced NSCLC patients previously treated with EGFR TKIs (first- or second-generation), especially in patients with T790M mutation (19, 20).